RPG Life Sciences trails healthcare peers on Q1 operating margin
Consolidated operating margin was 22.12%, 6.53 percentage points below the 10-peer median; management also flagged an API disruption from a fire.
Filed 28 Jul 2026, 20:21 IST · after market close · RPG Life Sciences Ltd (RPGLIFE)
Key takeaways
- RPG Life Sciences' consolidated operating margin of 22.12% was 6.53 percentage points below the median for 10 reported healthcare peers.
- Management said an API fire incident affected growth, while domestic formulations delivered market-beating growth and salesforce productivity exceeded 6.5 lakhs.
- Management said it is targeting immunosuppressant and Naprosyn portfolios of over Rs 200 crore and Rs 100 crore, respectively.
Price around the results
Q1 margin sits well below the healthcare peer median
RPG Life Sciences reported consolidated Q1FY27 revenue of Rs 195.69 cr and operating profit of Rs 43.29 cr, with an operating margin of 22.12%. That margin was 6.53 percentage points below the 28.65% median for 10 healthcare peers that had reported, placing the company third from the bottom. Other income was Rs 4.7 cr against profit before tax of Rs 41.46 cr, so reported earnings included a non-operating contribution.
API disruption was offset by domestic formulations momentum
Management said API growth was affected by a fire incident in one manufacturing block. The company also said domestic formulations delivered market-beating growth in Q1FY27, with salesforce productivity improving to above 6.5 lakhs. The commentary points to a mixed quarter across business lines rather than a uniform growth trend.
Portfolio expansion is focused on two named brands
Management said it aims to build the immunosuppressant portfolio to over Rs 200 crore and grow Naprosyn into a brand exceeding Rs 100 crore. The company also said it plans to enter new geographies and develop its new-launch pipeline. It reported more than Rs 185 crore of capex since FY22 to build a plant with EU, TGA and PMDA approvals.
Results were filed after market close
The consolidated results were filed on 28 Jul 2026 at 20:21 IST, after market close. A market reaction is therefore not included in this initial account.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹196 cr |
| Other income | ₹5 cr |
| Expenses | ₹152 cr |
| Operating profit | ₹43 cr |
| Operating margin (%) | 22.12% |
| Interest | ₹1 cr |
| Depreciation | ₹6 cr |
| Profit before tax | ₹41 cr |
| Tax | ₹11 cr |
| Net profit | ₹31 cr |
| EPS (₹) | ₹18.60 |
Operating margin of 22.12% compares with a Healthcare sector median of 28.65% across 10 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Domestic formulations delivered market-beating growth in Q1 FY27.
- Salesforce productivity in domestic formulations improved consistently and was above 6.5 lakhs.
Guidance & outlook
- The company aims to grow its immunosuppressant portfolio to over ₹200 crore.
- The company aims to grow Naprosyn into a brand exceeding ₹100 crore.
- The company plans to expand into new geographies and develop its new launch pipeline.
Expansion
- The company has infused more than ₹185 crore in capex since FY22 to build a modern approved plant.
New initiatives
- The company has multiple digital initiatives to streamline front-end and backend operations.
- The digital initiatives target efficiency, compliance, cost reduction and topline growth.
- The company has completed lab modernization and organizational expansion for its new product pipeline.
- The company is undertaking talent development and acquisition across key business and support functions.
Problems & risks
- API growth was impacted by a fire incident in one manufacturing block.
What to watch
- Whether operating margin narrows the 6.53 percentage-point gap with the 28.65% healthcare-peer median.
- Whether domestic-formulations salesforce productivity remains above 6.5 lakhs after the API fire incident.
- Progress against management's stated portfolio aims of over Rs 200 crore for immunosuppressants and over Rs 100 crore for Naprosyn.